Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
acknowledges postdoctoral fellowship support from the Ministry of Science and Innovation (MCIN, Spain) Juan de la Cierva program (IJC2020-043358-I)
This underscores that GSTM1 and GSTT1 genotypes are key determinants for stratifying individuals who would derive maximum benefit from SFN-based chemoprevention for colorectal cancer, with age and smoking history providing critical contextual refinement
Uric acid shown to contribute to increased oxidative stress level independent of Xanthine oxidoreductase activity in MedCity21 health examination registry
In contrast to the UGT1A subfamily, the members of the gene subfamily contain a different set of exons (Tukey & Strassburg, 2000)
